Cognitive Biases Under Ketamine

NCT ID: NCT02235012

Last Updated: 2024-07-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 84 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-09-08
• Study Completion Date: 2022-04-29

Brief Summary

Characterise cognitive biases resulting from low dose ketamine infusion, used as a pharmacological model of psychosis.

Our assumption is that low dose ketamine results in reasoning biases by impairing the way uncertainty is monitored and taken into account for decision making.

Detailed Description

Ketamine is a non-competitive glutamate NMDA antagonist. The infusion of subanesthetic doses of ketamine results in sub-clinical schizophrenia-like positive symptoms in healthy controls. The safety of ketamine use is attested by its daily use in child anesthesia and by a number of studies showing there is no medical, neural or cognitive complication after a single infusion.

Low dose ketamine is therefore a valid and safe human model to study psychosis. The objective of the study is to characterise cognitive biases resulting from low dose ketamine infusion, used as a pharmacological model of psychosis.

We designed four distinct paradigms designed to better characterize these biases.

P1 is a neuroeconomic task where subjects have to make binary choices to maximize gains, in a situation where either direct feedback information or additional counterfactual information is provided.

P2 is a neuroeconomic task where a direct manipulation of uncertainty is performed, and its impact on decision is measured.

P3 is a perceptual decision making task, where subjects have to classify a gabor orientation into the diagonal or cardinal category based on a rapidly presented series of individual gabors. The contribution of each piece of evidence to the final decision is measured and correlated to fluctuations in eeg data.

P4 is a perceptual decision making task, where subjects have to determine the global orientation of a series of sequentially presented gabor stimulus. There are interim responses and final responses, the influence of the former on the latter (confirmation bias) is studied.

Our assumption is that low dose ketamine results in reasoning biases by impairing the way uncertainty is monitored and taken into account for decision making.

The study design is as follows : randomized, double blind, controlled, against placebo, cross-over.

Healthy subjects will therefore be randomized to receive on the first visit either a ketamine infusion or a placebo infusion. The alternative condition will be applied on the second visit.

Ketamine will be prepared using KETAMINE PANPHARMA 250 mg/5mL, and infusion will be. This procedure should produce ketamine plasmatic levels of 140ng/ml. Two blood samples will be taken 30 and 90 minutes after infusion start to record actual ketamine plasmatic levels.

Placebo infusion will follow the same pattern of infusion, prepared using CHLORURE DE SODIUM 0,9% MACOPHARMA.

We will record both behavioral, electrophysiologic and psychometric data. Detailed assumptions are as folllows :

Behavioral data :

P1 and 2 : Significant impairment with ketamine in the ability to take into account uncertainty to guide decisions.

P3 : Significant decrease with ketamine in the ability to classify correctly the mean spatial orientation of stimuli according to the cardinal or diagonal direction.

P4 : Significant increase with ketamine in the confirmation bias following the interim choice.

Electroencephalographic data :

Correlation between the impairment in the ability to take into account uncertainty and the alteration of the Error Related Negativity and late inhibitory eeg signals, and decreased long distance synchrony as indicated by spectral analysis (P1 and 2).

The covariation of brain activity with the weight each stimuli sample will have in the final decision, will be increased as a result of ketamine infusion (P3).

Psychometric data :

Increase in the Brief Psychiatric Rating Scale (BPRS) as a result of ketamine infusion. The BPRS scale records the psychotic symtoms and is translated and validated in a french population sample.

Conditions

Healthy Subjects

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Ketamine then placebo

Infusion of low dose Ketamine then infusion of a saline solution

Group Type: EXPERIMENTAL

Ketamine

Intervention Type: DRUG

KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :

• Initial rapid infusion of 0,23 mg/kg
• Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
• Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Placebo

Intervention Type: DRUG

CHLORURE DE SODIUM 0,9 % MACOPHARMA :

• Initial rapid infusion of 0,23 mg/kg
• Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
• Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Placebo then ketamin

Infusion of a saline solution then infusion of low dose Ketamine

Group Type: EXPERIMENTAL

Ketamine

Intervention Type: DRUG

KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :

• Initial rapid infusion of 0,23 mg/kg
• Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
• Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Placebo

Intervention Type: DRUG

CHLORURE DE SODIUM 0,9 % MACOPHARMA :

• Initial rapid infusion of 0,23 mg/kg
• Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
• Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Interventions

Ketamine

KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :

• Initial rapid infusion of 0,23 mg/kg
• Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
• Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Intervention Type: DRUG

Placebo

CHLORURE DE SODIUM 0,9 % MACOPHARMA :

• Initial rapid infusion of 0,23 mg/kg
• Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
• Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Right-handed (as assessed by the Edinburgh scale)
• Aged 18 to 39
• Having given an informed consent
• Health insurance

Exclusion Criteria

• Pregnant or breastfeeding woman (a urine pregnancy test will be offered in doubt)
• Personal or first-degree family history of psychosis
• Personal history of mood disorder, anxiety disorder, obsessive-compulsive disorder, somatoform disorder, dependence on a psychoactive substance, behavior disorder incompatible with a 2 hours EEG recording.
• Psychotropic treatment, current or stopped for less than 1 month, including antidepressant, anxiolytic but excluding hypnotic treatments.
• Personal history of neurologic disorder in relation to the central nervous system : congenital malformation of the brain, brain tumor, multiple sclerosis, degenerative disease of the central nervous system, epilepsy, current or in remission for less than 3 years or still requiring a medical treatment, inflammatory disease of the central nervous system dating under a year or having resulted in sequelae.
• Known hypertension or blood pressure above 140/90 mmHg upon clinical examination, congenital heart disease, ischemic heart disease, cardiac insufficiency, supraventricular and ventricular heart rhythm disorder.
• Person with restricted liberty, as a result of judicial or administrative measures
• Persons under involuntary commitment as a result of a psychiatric disorder.
• Person subject to a measure of legal protection or unable to consent.
• Known intolerance ketamine.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 39 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Fondation pour la Recherche Médicale

OTHER

Sponsor Role: collaborator

Fondation Fyssen

UNKNOWN

Sponsor Role: collaborator

Comité pour la Recherche Hospitalière Médicale

UNKNOWN

Sponsor Role: collaborator

Association Schizo Oui

UNKNOWN

Sponsor Role: collaborator

Centre Hospitalier St Anne

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Raphaël GAILLARD

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier St Anne

Locations

Centre Hospitalier Sainte Anne

Paris, , France

Countries

France

Other Identifiers

2013-002056-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

D512

Identifier Type: -

Identifier Source: org_study_id